Objective To evaluate the prognostic value of serum tissue factor pathway inhibitor-1(TFPI-1)combined with nuclear factor-κB(NF-κB)in severe traumatic brain injury(STBI).Methods The medical re-cords of 127 patients with STBI admitted to the hospital from July 2022 to August 2024 were retrospectively ana-lyzed and followed up for 6 months.They were divided into poor prognosis group(n=53)and good prognosis group(n=74)according to the prognosis of STBI patients.The serum NF-κB level,clinical data and serum TFPI-1 level of the two groups were compared.The factors affecting the adverse prognosis of STBI patients was screened,and the value of serum NF-κB and serum TFPI-1 in predicting the adverse prognosis of STBI patients were ana-lyzed.Results The serum NF-κB level in the poor prognosis group was higher than good prognosis group,and the serum TFPI-1 level was lower than good prognosis group(P<0.05).The proportion of patients aged>60 years old was higher than good prognosis group(P<0.05).Serum TFPI-1 level(OR=0.328,95%CI:0.156～0.689)was a protective factor for poor prognosis in STBI patients(P<0.05),serum NF-κB level(OR=3.773,95%CI:1.797～7.924)and age>60 years(OR=3.543,95%CI:1.687～7.441)were independent risk factors for poor prognosis in STBI patients(P<0.05).The area under the curve(AUC)of serum TFPI-1 and NF-κB levels and their combined prediction of poor prognosis in STBI patients were 0.784,0.847 and 0.931,respectively(P<0.05),and the AUC value of the combined TFPI-1 and NF-κB levels was higher(P<0.05).Conclusion Serum NF-κB combined with serum TFPI-1 has higher prognostic value in STBI patients.

Objective To evaluate the prognostic value of serum tissue factor pathway inhibitor-1(TFPI-1)combined with nuclear factor-κB(NF-κB)in severe traumatic brain injury(STBI).Methods The medical re-cords of 127 patients with STBI admitted to the hospital from July 2022 to August 2024 were retrospectively ana-lyzed and followed up for 6 months.They were divided into poor prognosis group(n=53)and good prognosis group(n=74)according to the prognosis of STBI patients.The serum NF-κB level,clinical data and serum TFPI-1 level of the two groups were compared.The factors affecting the adverse prognosis of STBI patients was screened,and the value of serum NF-κB and serum TFPI-1 in predicting the adverse prognosis of STBI patients were ana-lyzed.Results The serum NF-κB level in the poor prognosis group was higher than good prognosis group,and the serum TFPI-1 level was lower than good prognosis group(P<0.05).The proportion of patients aged>60 years old was higher than good prognosis group(P<0.05).Serum TFPI-1 level(OR=0.328,95%CI:0.156～0.689)was a protective factor for poor prognosis in STBI patients(P<0.05),serum NF-κB level(OR=3.773,95%CI:1.797～7.924)and age>60 years(OR=3.543,95%CI:1.687～7.441)were independent risk factors for poor prognosis in STBI patients(P<0.05).The area under the curve(AUC)of serum TFPI-1 and NF-κB levels and their combined prediction of poor prognosis in STBI patients were 0.784,0.847 and 0.931,respectively(P<0.05),and the AUC value of the combined TFPI-1 and NF-κB levels was higher(P<0.05).Conclusion Serum NF-κB combined with serum TFPI-1 has higher prognostic value in STBI patients.

As a new generation of negative pressure drainage technology, vacuum-assisted closure (VAC) can provide stable and persistent negative pressure, and there are several modes to choose from. VAC plays an important role in closing wounds quickly, controlling infection, promoting angiogenesis, increasing blood flow, and promoting granulation tissue growth of wounds. It is now widely applied in all kinds of acute, chronic, and special wounds in clinic with good therapeutic results. However, we need to pay attention to contraindications and complications of VAC when it is used, avoiding secondary damage due to improper treatment. In this review, we summarize VAC dressings, treating pressure and mode choice, mechanism in promoting wound healing, and clinical application of VAC.